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Abstract
Background: To study the relationship between the intima-media thickness (IMT) of the carotid artery and the stage 
of chronic kidney disease (CKD) based on the estimated glomerular filtration rate (eGFR) and diabetic nephropathy 
graded by the urinary albumin excretion (UAE) in the patients with type 2 diabetes mellitus.
Methods: A cross-sectional study was performed in 338 patients with type 2 diabetes mellitus. The carotid IMT was 
measured using an ultrasonographic examination.
Results: The mean carotid IMT was 1.06 ± 0.27 mm, and 42% of the subjects showed IMT thickening (≥ 1.1 mm). 
Cerebrovascular disease and coronary heart disease were frequent in the patients with IMT thickening. The carotid IMT 
elevated significantly with the stage progression of CKD (0.87 ± 0.19 mm in stage 1, 1.02 ± 0.26 mm in stage 2, 1.11 ± 
0.26 mm in stage 3, and 1.11 ± 0.27 mm in stage 4+5). However, the IMT was not significantly different among the 
various stages of diabetic nephropathy. The IMT was significantly greater in the diabetic patients with hypertension 
compared to those without hypertension. The IMT positively correlated with the age, the duration of diabetes mellitus, 
and the brachial-ankle pulse wave velocities (baPWV), and negatively correlated with the eGFR. In a stepwise 
multivariate regression analysis, the eGFR and the baPWV were independently associated with the carotid IMT.
Conclusions: Our study is the first report showing a relationship between the carotid IMT and the renal parameters 
including eGFR and the stages of diabetic nephropathy with a confirmed association between the IMT and diabetic 
macroangiopathy. Our study further confirms the importance of intensive examinations for the early detection of 
atherosclerosis and positive treatments for hypertension, dyslipidaemia, obesity, as well as hyperglycaemia are 
necessary when a reduced eGFR is found in diabetic patients.
Background
Diabetic nephropathy is a major manifestation of
microangiopathy that plays a significant role in the prog-
nosis of patients with diabetes mellitus. An increased
number of individuals with end-stage renal failure caused
by diabetic nephropathy present a large social problem.
Diabetic nephropathy is graded according to the urinary
albumin excretion rate (UAE). Microalbuminuria as well
as macroalbuminuria are important markers for the pro-
gression of renal dysfunction and are currently recog-
nized as predictive factors for cardiovascular adverse
events [1-3].
Recently, it has become possible to evaluate the glomer-
ular filtration rate (GFR) using a formula to calculate the
estimated GFR (eGFR) in Japanese subjects [4]; although
serum creatinine levels and the creatinine clearance rate
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have long been used for the evaluation of kidney func-
tion. Chronic kidney disease (CKD) is defined as the
decrease in eGFR (<60 mL/min/1.73 m2) for 3 months or
more and/or persistent proteinuria [5]. The stages of
CKD are based only on the GFR and it is also acknowl-
edged that the risk of a cardiovascular event increases
with the progression of the CKD stage.
The measurement of the intima-media thickness (IMT)
enables the detection of atherosclerotic lesions of the
arterial walls. It is well-known that atherosclerotic dis-
eases frequently occur in diabetic patients as diabetic
macroangiopathy. In patients with type 2 diabetes melli-
tus, the carotid IMT is significantly greater than in the
corresponding healthy, age- and sex-matched, non-dia-
betic subjects [6-9]. A small increase in the IMT of the
carotid artery predicts coronary heart disease and stroke
even after an adjustment for cardiovascular risk factors
[10]. Therefore, the IMT is considered to reflect an early
stage of macroangiopathy in diabetic patients. The
carotid IMT was used as a surrogate marker of diabetic
macroangiopathy in the cohort study because the num-
ber of macrovascular events was rather small [11].
Several studies have reported the IMT to increase with
the progression of diabetic nephropathy; however, the
relationship of the IMT with the UAE is still controversial
[12-17]. An association of the IMT with both the UAE
and the GFR in diabetic patients has been investigated in
a few reports [12,17]. Previous investigations did not
observe a relationship between the IMT and the renal
parameters after an association between the IMT and
diabetic macroangiopathies was reported in a single
study.
The aim of this study was to investigate the relationship
of the carotid IMT with the clinical backgrounds, includ-
ing diabetic complications, stages of CKD, and diabetic
nephr opa th y , of J a panese pa tients wit h type 2 dia bet es
mellitus.
Methods
A cross-sectional study was performed in a population of
338 patients diagnosed with type 2 diabetes mellitus
under consecutive evaluations, including urinalysis,
serum creatinine levels, and ultrasonographic examina-
tions for the carotid artery at the Department of Diabe-
tes, Metabolism and Kidney Diseases of Edogawa
Hospital, Tokyo, Japan between April 2008 and March
2009. The patients with end-stage renal disease receiving
maintenance dialysis were excluded from this study
because it is more difficult to evaluate clinical parameters
such as blood pressure, body weight, serum creatinine
and lipid concentrations in these patients compared with
those not on dialysis. Subjects who underwent physical
health examinations were also entered into the study as
normal controls (age-matched 37 men and 30 women).
They did not have diabetes mellitus, hypertension, hyper-
lipidaemia and the history of myocardial and/or cerebral
infarction.
The eGFR was calculated using the formula reported by
M a t s u o  e t  a l  [ 4 ] .  T h i s  e q u a t i o n  o r i g i n a t e d  f r o m  t h e
MDRD study group [18] arranged for Japanese individu-
als, and it is recommended by the Japanese Society of
Nephrology: eGFR (mL/min/1.73 m2) = 194 × Scr-1.094 ×
Age-0.287 × 0.739 (if female). The stages of CKD were
based on the NKF K/DOQI clinical practice guidelines
[5].
The UAE is presented as the albumin-to-creatinine
ratio (ACR; mg/g creatinine). Diabetic nephropathy was
staged according to an analysis of a spot urine sample as:
DN stage I (normoalbuminuria), ACR < 30 mg/g creati-
nine; DN stage II (microalbuminuria), 30 ≤ ACR < 300
mg/g creatinine; DN stage III (macroalbuminuria), ACR
≥ 300 mg/g creatinine (or dipstick urinalysis revealed 2+,
3+ or 4+) and eGFR ≥ 30 mL/min/1.73 m2; and DN stage
IV, ACR ≥ 300 mg/g creatinine (or dipstick urinalysis
revealed 2+, 3+ or 4+) and eGFR < 30 mL/min/1.73 m2.
The individuals who had additional kidney diseases, such
as acute renal failure, chronic glomerulonephritis and
interstitial nephritis, were excluded from this study.
The blood pressure was measured twice with the sub-
jects in the sitting position after a 5-minute rest. The
lower value of the two measurements was used for the
study. Hypertension was defined as a systolic blood pres-
sure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90
mmHg. The participants currently using antihyperten-
sive medications were also classified as positive for
hypertension. Hyperlipidaemia was defined by serum
concentrations of total cholesterol ≥ 5.7 mmol/L, LDL-
cholesterol ≥ 3.6 mmol/L or as patients already being
treated with lipid-lowering agents.
Diabetic retinopathy was defined as a simple retinopa-
thy or as more severe conditions, which was judged
according to the results of a funduscopic examination
performed by expert ophthalmologists. Diabetic neurop-
athy was diagnosed by the presence of two or more com-
ponents among clinical symptoms (bilateral spontaneous
p a i n ,  h y p o a e s t h e s i a ,  o r  p a r a e s t h e s i a  o f  t h e  l e g s ) ,  t h e
absence of ankle tendon reflexes and decreased vibration
sensations using a C128 tuning fork. Cerebrovascular dis-
ease was diagnosed by the physicians as a history of an
ischaemic stroke using brain computed tomography or
magnetic resonance imaging. Only the patients with
symptoms were classified as having cerebrovascular dis-
ease, and cases of silent brain infarction, transient ischae-
mic attack or brain haemorrhage were excluded from this
study. Coronary heart disease was diagnosed based on a
previous history of myocardial infarction, angina pecto-
ris, electrocardiogram abnormalities suggesting myocar-
dial ischaemia or interventions after coronaryIto et al. Cardiovascular Diabetology 2010, 9:18
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angiographic examination. Peripheral arterial disease was
diagnosed by the absence of a pulse in the legs along with
ischaemic symptoms, obstructive findings on an ultra-
sonographic examination of the lower extremities, or
ankle-brachial pressure index (ABI) < 0.9.
The ABI and brachial-ankle pulse wave velocities
(baPWV) as indicators of atherosclerosis were measured
using Form PWV/ABI, BP-203PRE II (Omron Colin Co.,
Ltd, Bunkyo, Tokyo, Japan).
The IMT of the carotid artery was measured with ultra-
sonographic examinations by skilled laboratory techni-
cians using Aplio XV ultrasound machine (Toshiba
Medical Systems Corp., Ohtawara, Tochigi, Japan). B-
mode imaging of the carotid artery was performed with a
7.5 MHz probe. The distal common carotid artery and
the carotid bulb were identified by longitudinal scanning
in the supine position with the head slightly extended and
turned to the oppose direction. The IMT was defined as
the distance between the leading edges of the lumen
interface and the media-adventitia interface at the far
wall. IMT was not measured at the site of the atheroma-
tous plaques. The bilateral common carotid and the
internal carotid arteries were assessed by 2 different
(anterior-posterior and lateral) longitudinal projections.
The representative IMT was expressed as the maximal
value of the measurements at any location in the carotid
arteries (max IMT). The final value of the IMT was calcu-
lated as an average of the max IMT on both sides in this
study. Although the carotid IMT increases with age, it
does not rise above 1.0 mm in normal Japanese adults.
Therefore, the presence of increased IMT (IMT thicken-
ing) in the carotid artery has been defined as an IMT of ≥
1.1 mm [8].
Statistical analysis
An analysis of variance (ANOVA) and the χ2 test were
used for between-group comparisons of the continuous
and categorical variables, respectively. Pearson's univari-
ate regression analysis and stepwise multivariate regres-
sion analysis by the forward selection method were
performed to determine the association of the carotid
IMT with the other clinical parameters. Differences with
P < 0.05 (two-tailed) were considered to be statistically
significant. The statistical software package JMP, version
8.0 (SAS Institute, Cary, NC, USA), was used to perform
all of the analyses.
Results
Table 1 shows the clinical characteristics and the labora-
tory parameters of the patients. The mean carotid IMT
was significantly greater in the study subjects than in the
normal controls (1.06 ± 0.27 mm versus 0.94 ± 0.30 mm,
P = 0.04).
Table 2 shows the comparison of the clinical character-
istics between the patients with and without carotid IMT
thickening. The frequencies of IMT thickening were sig-
nificantly higher in the patients than in the normal con-
trols (42% versus 29%, P = 0.02).
The age, duration of diabetes mellitus, incidence of
hypertension, and baPWV were significantly higher in
the patients with IMT thickening than in those without
IMT thickening. The patients receiving treatment with
the angiotensin II receptor blocker (ARB) and the cal-
cium channel blocker (CCB) were more frequent in the
IMT thickening group than in the group without IMT
thickening. The eGFR was significantly lower in the
patients with IMT thickening than those without IMT
thickening, and the incidence of IMT thickening
increased with the stage progression of CKD. The preva-
lence of diabetic macroangiopathy manifesting as cere-
brovascular disease and coronary heart disease was
significantly higher in the patients with IMT thickening
than in those without IMT thickening. However, there
was no association between the stage of diabetic neph-
ropathy based on the UAE and thickening of the IMT.
The elevated carotid IMT significantly correlated with
the stage progression of CKD (0.87 ± 0.19 mm in stage 1,
1.02 ± 0.26 mm in stage 2, 1.11 ± 0.26 mm in stage 3, and
1.11 ± 0.27 mm in stage 4+5, P < 0.01). However, the IMT
was not significantly different among the patients at dif-
ferent stages of diabetic nephropathy (1.04 ± 0.27 mm in
DN stage I, 1.06 ± 0.26 mm in DN stage II, 1.06 ± 0.26
mm in DN stage III, and 1.11 ± 0.28 mm in DN stage IV).
Figure 1 shows the IMT among the subgroups that are
divided by the stages of CKD and diabetic nephropathy.
The IMT increased with the stage progression of CKD in
each stage of diabetic nephropathy (P = 0.03 in DN stage I
and P = 0.01 in DN stage II).
Figure 2 shows the relationships between the carotid
IMT and clinical parameters. The IMT positively corre-
lated with age, duration of diabetes mellitus, and baPWV
and negatively correlated with eGFR. The level of the
eGFR that the IMT was equivalent to 1.1 mm was 41.3
mL/min/1.73 m2 according the formula of the correlation
(y = -0.0025729x + 1.2064048). In a stepwise multivariate
regression analysis, the IMT was used a continuous vari-
able. The following factors were entered as independent
variables showing a significant correlation with IMT in
the univariate analyses: the duration of diabetes mellitus,
the eGFR, the baPWV, and hypertension (absent = 0,
present = 1). Because the eGFR is already corrected by
age, the patient's age was excluded from this analysis. The
eGFR and the baPWV were independently associated
with the carotid IMT (F = 5.53 and 6.34, P = 0.02 and
0.01, respectively, r = 0.29).Ito et al. Cardiovascular Diabetology 2010, 9:18
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Table 1: Clinical characteristics of the patients.
%/Mean (SD) Number estimated (%)
Age (years) 65 (11) 338 (100)
Men 64 338 (100)
Duration of diabetes mellitus (years) 11 (10) 254 (75)
Current plus past smoking 57 282 (83)
Current drinker 43 268 (79)
Therapeutic method for diabetes mellitus 338 (100)
Diet only/OHA/Insulin 4/51/44
Body mass index (kg/m2) 24.4 (4.4) 333 (99)
Obesity# 36 333 (99)
Hypertension 78 338 (100)
Systolic blood pressure (mmHg) 132 (19) 338 (100)
Diastolic blood pressure (mmHg) 76 (12) 338 (100)
Antihypertensive agents 338 (100)
ACEi 19
ARB 46
CCB 48
Hyperlipidaemia 73 338 (100)
Statin 54
HbA1c (%) 7.2 (1.7) 316 (94)
Total cholesterol (mmol/L) 4.9 (1.1) 262 (78)
LDL cholesterol (mmol/L) 2.9 (1.0) 297 (88)
HDL cholesterol (mmol/L) 1.5 (0.4) 299 (89)
Serum creatinine (μmol/L) 92 (69) 338 (100)
Estimated GFR (mL/min/1.73 m2) 57.5 (21.5) 338 (100)
CKD stage 338 (100)
Stage 1 5
Stage 2 45
Stage 3 39
Stage 4+5 11
Diabetic retinopathy$ 45 254 (75)
Diabetic neuropathy 84 256 (76)
Cerebrovascular disease 23 336 (99)
Coronary heart disease 21 337 (100)
Peripheral arterial disease 4 338 (100)
Diabetic nephropathy 321 (95)
Stage I 47
Stage II 25
Stage III 17
Stage IV 11
ABI 1.1 (0.1) 240 (71)
baPWV (cm/s) 1794 (397) 239 (71)
IMT (mm) 1.06 (0.27) 338 (100)
OHA: oral hypoglycemic agents, ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, CCB: calcium channel 
blocker, GFR: glomerular filtration rate, CKD: chronic kidney disease, ABI: ankle-brachial index, and baPWV: brachial-ankle pulse wave velocity.
# Obesity includes individuals with BMI ≥ 25 kg/m2.
$ Diabetic retinopathy includes simple, pre-proliferative, and proliferative retinopathies.Ito et al. Cardiovascular Diabetology 2010, 9:18
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The baPWV also positively correlated with age (r  =
0.44, P < 0.01) and the duration of diabetes mellitus (r =
0.23, P < 0.01) and negatively correlated with the eGFR (r
= -0.32, P < 0.01). It was significantly higher in the dia-
betic patients with hypertension than in those without
hypertension (1863 ± 394 cm/s vs. 1554 ± 301 cm/s, P <
0.01).
Discussion
Based on univariate analyses in the present study, the
clinical parameters associated with the IMT were age, the
duration of diabetes mellitus, hypertension, the stage of
CKD according to the eGFR, and the baPWV. However,
the strength of the correlation was weak (r  = -0.20)
between the IMT and eGFR levels. Although the subjects
with CKD (eGFR < 60 mL/min/1.73 m2) are considered to
be high risk patients for atherosclerotic vascular diseases,
diabetic patients with an eGFR < 40 mL/min/1.73 m2 may
have an IMT ≥ 1.1 mm according to the formula deter-
mined for the correlation. The stage of diabetic nephrop-
athy according to the UAE was not associated with the
IMT in this study. On the other hand, cerebrovascular
disease and coronary heart disease were significantly
more frequent in the group with IMT thickening than
that without IMT thickening. These results are in accor-
dance with the use of the IMT as a surrogate marker of
atherosclerotic diseases.
Agewell  et al. reported a significant association
between the carotid IMT and the UAE in 368 healthy 58-
year old males [19]. In the random population which
included diabetic patients, the carotid IMT was also
related to the UAE, although the evaluation of renal func-
tions, such as the GFR was not investigated [20,21].
Kawamoto  et al. demonstrated a negative correlation
between the carotid IMT and the eGFR without an exam-
ination for the UAE [22]. Hermans et al. showed that the
carotid IMT was significantly associated with both the
UAE and the eGFR in 806 subjects, including 181 subjects
with impaired glucose tolerance and 326 with type 2 dia-
betes mellitus.
However, the significance disappeared after an adjust-
ment by the other parameters, such as subject's age [23].
Preston  et al. reported that the carotid IMT increased
with the attenuation of the eGFR in 104 CKD patients,
including 33 diabetic patients, with a serum creatinine
level > 125 μmol/L. They also did not find an association
between the IMT and the UAE [24].
Several studies were performed to investigate the asso-
ciation between the IMT and the clinical parameters in
the patients with type 2 diabetes mellitus [12-17,25].
Taniwaki  et al. reported that the IMT was not different
between the groups with normoalbuminuria and
microalbuminuria but that it was negatively correlated
with the eGFR in 61 patients with type 2 diabetes mellitus
[12]. Yokoyama et al. and Keech et al. demonstrated that
I M T  e l e v a t e d  w i t h  a n  i n c r e a s e  i n  t h e  U A E  [ 1 3 , 1 4 ] ,
although Mykkänen et al. and Ishimura et al. reported
that the IMT did not correlate with UAE [9,15]. Dong et
al. observed a significant association between the IMT
and the eGFR in 1,009 Chinese diabetic patients without
an evaluation of the UAE [16]. Freedman et al. reported
that carotid IMT did not differ among the groups with
normoalbuminuria, microalbuminuria, and macroalbu-
minuria in 588 white participants with type 2 diabetes
mellitus [17]. Our results also indicate that the IMT nega-
tively correlated with the eGFR. Moreover, our study is
the first report showing a relationship between the
carotid IMT and the renal parameters including eGFR
and the stages of diabetic nephropathy with a confirmed
association between the IMT and macroangiopathy.
Although previous studies have not refuted a relationship
between the IMT and the GFR, an association between
the IMT and the stage of diabetic nephropathy based on
the UAE showed a discrepancy. This might be explained
by the differences in the patients' background, such as age
a n d  d u r a t i o n  o f  t h e  i l l n es s.  F u rt h e rm o r e ,  i t  is  pos s i b l e
that individuals with an increased UAE and IMT died
prior to inclusion into this study. Recently, it was
reported that both the decreased eGFR and proteinuria
are independently associated with cardiovascular events
in both the random population [26] and in the patients
with type 2 diabetes mellitus [27]. Our results and the
discrepancies in the previous reports might be explained
if the effect on cardiovascular events is stronger in the
subjects with the decreased eGFR than in those with pro-
teinuria. However, further studies will be needed to con-
firm this.
It was recently reported that the IMT was significantly
associated with diabetic neuropathy [25]. The IMT was
not different between the patients with and without dia-
betic microangiopathy, including diabetic neuropathy in
this study. The older age and the high frequency of dia-
betic neuropathy of the patients in this study might be the
reason for the different result.
In this study, the patients receiving treatment with the
ARB and the CCB were frequent in the group with IMT
thickening compared to the group without IMT thicken-
ing. This indicates that more antihypertensive agents
were necessary in the group with IMT thickening to
reduce blood pressure because of the similar systolic and
diastolic blood pressure between the two groups (Table
2).
The beneficial effects of the renin-angiotensin system
(RAS) inhibitors for renal dysfunction and vascular
adverse events are widely recognized. It was reported that
telmisartan, one of the ARBs, reduced the IMT compared
to amlodipine in the hypertensive patients with CKD
[28]. The ARB might be useful in the diabetic patientsIto et al. Cardiovascular Diabetology 2010, 9:18
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Table 2: Clinical characteristics between the diabetic patients with and without IMT thickening.
%/Mean (SD)
IMT < 1.1 mm IMT ≥ 1.1 mm P
(n = 195) (n = 143)
Age (years) 62 (12) 69 (9) < 0.01
Men 64 65 0.78
Duration of diabetes mellitus (years) 9 (8) 13 (12) < 0.01
Current plus past smoking 57 58 0.99
Current drinker 42 43 0.66
Therapeutic method for diabetes mellitus
Diet only/OHA/Insulin 5/50/45 4/51/45 0.75
Body mass index (kg/m2) 24.7 (4.7) 24.1 (3.8) 0.19
Obesity# 37 34 0.53
Hypertension 73 85 < 0.01
Systolic blood pressure (mmHg) 132 (18) 133 (21) 0.40
Diastolic blood pressure (mmHg) 76 (12) 76 (12) 0.67
Antihypertensive agents
ACEi 20 19 0.89
ARB 41 52 0.04
CCB 43 54 0.04
Hyperlipidaemia 75 71 0.38
Statin 55 54 0.85
HbA1c (%) 7.2 (1.7) 7.3 (1.7) 0.40
Total cholesterol (mmol/L) 4.9 (1.1) 5.0 (1.1) 0.29
LDL cholesterol (mmol/L) 2.9 (1.0) 3.0 (0.9) 0.25
HDL cholesterol (mmol/L) 1.5 (0.4) 1.4 (0.3) 0.31
Serum creatinine (μmol/L) 99 (81) 110 (76) 0.22
Estimated GFR (mL/min/1.73 m2) 61.0 (21.6) 52.8 (20.6) < 0.01
CKD stage < 0.01
Stage 1 7 2
Stage 2 52 36
Stage 3 33 48
Stage 4+5 8 15
Diabetic retinopathy$ 40 50 0.096
Diabetic neuropathy 84 84 0.87
Cerebrovascular disease 19 28 0.04
Coronary heart disease 17 27 0.02
Peripheral arterial disease 4 5 0.55
Diabetic nephropathy 0.28
Stage I 49 46
Stage II 25 24
Stage III 19 16
Stage IV 7 14
ABI 1.1 (0.1) 1.1 (0.1) 0.27
baPWV (cm/s) 1736 (403) 1876 (375) < 0.01
OHA: oral hypoglycemic agents, ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, CCB: calcium channel 
blocker, GFR: glomerular filtration rate, CKD: chronic kidney disease, ABI: ankle-brachial index, and baPWV: brachial-ankle pulse wave velocity.
# Obesity includes individuals with BMI ≥ 25 kg/m2.
$ Diabetic retinopathy includes simple, pre-proliferative, and proliferative retinopathies.Ito et al. Cardiovascular Diabetology 2010, 9:18
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with both an IMT thickening and a decreased eGFR for
the prevention of vascular events as well as a renoprotec-
tive effect. Other investigators reported that amlodipine
also decreased the IMT in the hypertensive patients
[29,30]. Furthermore, Ikeda et al. reported that amlodop-
ine significantly decreased the IMT compared to losartan
in 104 hypertensive patients with type 2 diabetes [31]. It
is unclear whether this discrepancy is caused by the dif-
ferent backgrounds of the study subjects and whether the
different effects are observed among the ARBs. Statin was
also reported to reduce the IMT in the patients with
CKD, including diabetes mellitus [32]. In this study, the
effects of the antihypertensive agents and statin for the
prevention of diabetic complications were not able to be
evaluated because our study is based on a cross-sectional
study with the patients receiving the treatments prior to
the study.
The baPWV is another measure of atherosclerosis.
While the IMT provides a measure of the arterial thick-
ening, baPWV reflects arterial stiffness and is a marker of
both the severity of vascular damage and the prognosis of
atherosclerotic disease in the patients with diabetes mel-
litus [32]. The IMT showed a significant positive correla-
tion with the baPWV in our study. This finding is in
accordance with previous studies [6,13,15]. Both an IMT
thickening and an increased baPWV are likely to reflect
the early stages of atherosclerosis. Because the eGFR was
associated with both the IMT and the baPWV in this
study, the eGFR might be another useful surrogate
marker for vascular events in the patients with diabetes
mellitus.
Yamashina et al. reported that a baPWV > 1400 cm/s is
an independent risk factor for atherosclerotic cardiovas-
cular disease [33]. Because the baPWV levels were high
in both groups with and without IMT thickening, the
study subjects of this study were considered to be at an
increased risk for vascular events. However, the mean
IMT was within the normal range in this study. The dis-
Figure 1 The IMT of the subgroups divided by the stages of CKD and diabetic nephropathy. The IMT increased with the stage progression of 
CKD in each stage of diabetic nephropathy (P = 0.03 in DN stage I and P = 0.01 in DN stage II).Ito et al. Cardiovascular Diabetology 2010, 9:18
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crepancy in the level of risk and IMT might have been
caused by the factors which influence the baPWV, such as
arterial calcification and hypertension.
The results of this study have several limitations that
must be considered. First, the findings are inherently lim-
ited by an inability to eliminate causal relationships
between the risk factors and carotid IMT thickening
because of the cross-sectional design. Although cerebro-
vascular and coronary heart diseases were frequent in the
patients with carotid IMT thickening, this study did not
examine diabetic macroangiopathies as the direct vascu-
lar endpoints. The effects of drugs, such as antihypeten-
sive agents and statin, were also not able to be evaluated.
Therefore, our data can not provide the mechanisms for
the observed associations between the clinical parame-
ters and the IMT. It should be noted that our results are
unable to explain the potential confounding effects of the
RAS inhibitors and statin on the arterial remodeling pro-
cess. Second, the evaluations of the eGFR, the UAE and
the IMT were performed according to a single assess-
ment of the serum creatinine level, the urinary albumin
concentration, and the carotid artery ultrasonography.
We also have to be mindful of to the possibility of either
misclassification or bias in the staging of diabetic neph-
ropathy and CKD. Third, there were some missing data
with regard to the duration of diabetes mellitus, smoking
history and baPWV. It is also possible that an error could
have occurred during the multivariate analysis.
In conclusion, intensive examinations to improve the
early detection of atherosclerosis, and earlier treatments
for hypertension, dyslipidaemia, and obesity as well as
hyperglycaemia are necessary to prevent future cardio-
vascular adverse events when a reduced eGFR related
with IMT thickening is found in the patients with type 2
diabetes mellitus. However, further studies investigating
Figure 2 Correlation of the IMT to the clinical parameters. The IMT positively correlated with age, duration of diabetes mellitus, and baPWV and 
negatively correlated with eGFR. The level of the eGFR that the IMT was equivalent to 1.1 mm was 41.3 mL/min/1.73 m2 according the formula of the 
correlation (y = -0.0025729x + 1.2064048).Ito et al. Cardiovascular Diabetology 2010, 9:18
http://www.cardiab.com/content/9/1/18
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the clinical outcomes are needed because this study is
based on a cross-sectional design.
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